Switzerland's Galenica 2025 sales rise 5.5%; expects 2026 sales growth of 5% to 7%

Galenica AG

10/03/2026 05:50

Overview

Swiss healthcare firm's 2025 sales rose 5.5%, reaching CHF 4,135.6 mln

Adjusted EBIT for 2025 grew 11.3% to CHF 234.8 mln

Company raises mid-term EBIT guidance to CHF 270 mln by 2027

Outlook

Galenica expects 2026 sales growth of 5% to 7%

Company forecasts 2026 adjusted EBIT growth of 6% to 8%

Galenica raises mid-term EBIT guidance to CHF 270 mln for 2027

Result Drivers

PHARMACY SERVICES - Expansion of consultation services and new insurance partnerships boosted pharmacy segment

WHOLESALE EFFICIENCY - Modernized systems in wholesale improved efficiency and logistics

DIAGNOSTICS EXPANSION - Acquisition of Labor Team expanded diagnostics offerings and growth potential

Company press release: ID:nEQ1ds79na

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted EBIT
CHF 234.80 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Galenica AG is CHF88.00, about 6.3% below its March 9 closing price of CHF93.90

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 23 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)